Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in caucasian spanish liver transplant patients

Journal of Clinical Pharmacology

Volumn 53, Issue 11, 2013, Pages 1146-1154

  Gómez Bravo, Miguel Angel ^a   Salcedo, Magdalena ^b   Fondevila, Constantino ^c   Suarez, Francisco ^d   Castellote, José ^e   Rufian, Sebastian ^f   Pons, José Antonio ^g   Alamo, José María ^a   Millán, Olga ^h,i   Brunet, Mercè ^c,h,i  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Liver Transplant Unit   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

BPAR; Drug disposition; Ethnicity; Metabolism; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ABCB1 GENE; ACUTE GRAFT REJECTION; ADULT; ARTICLE; BIOPSY PROVEN ACUTE REJECTION; CADAVER; CAUCASIAN; CYP3A5 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; HOMOZYGOTE; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ORGAN DONOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

BPAR; DRUG DISPOSITION; ETHNICITY; METABOLISM; PHARMACOGENETICS;

CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; TISSUE DONORS;

EID: 84892913295     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.154     Document Type: Article

References (35)

1. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and Pglycoprotein. Clin Pharmacokinet. 2001;40 3: 159-168.
2. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough bloood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:471-478.
3. Cummins CL, Salphati L, Reid MJ, Benet LZ. In vivo modulation of intestinal CYP3A metabolism by Pglycoprotein: Studies using the rat singlepass intestinal perfusion model. J Pharmacol Exp Ther. 2003;305 1: 306-314.
4. MacPhee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: The CYP3A5-1 allele predicts low dosenormalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005;79:499-502.
5. Chowbay B, Zhou S, Lee EJ. An interethnic comparison of polymorphisms of the genes encoding drugmetabolizing enzymes and drug transporters: Experience in Singapore. Drug Metab Rev. 2005;37 2: 327-378.
6. Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: A window into diversity. Pharmacogenomics. 2011;12 12: 1663-1670.
7. Rahsaz M, Azarpira N, Nikeghbalian S, et al. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population. Exp Clin Transplant. 2012;10:24-29.
8. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010;49 3: 141-175.
9. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet. 2010;49 4: 207-221.
10. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus doseadjusted trough levels and acute rejection rates in renal transplant patients: A systematic review and metaanalysis. Pharmacogenet Genomics. 2012;22 8: 642-645.
11. Hesselink DA, van Schaik RH, van der Heiden IP. et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254.
12. Op den Buijsch RA, Christiaans MH, Stolk LM, et al. Tacrolimus pharmacokinetics and pharmacogenetics: Influence of adenosine triphosphate binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007;21:427-435.
13. Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study. Am J Transplant. 2006;6:2706-2713.
14. Ferraresso M, Tirelli A, Ghio L, et al. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant. 2007; 11:296-300.
15. Fukudo M, Yano I, Masuda S, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric livingdonor liver transplant recipients. Clin Pharmacol Ther. 2006;80:331-345.
16. Goto M, Masuda S, Kiuchi T, et al. CYP3A5-1carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of livingdonor liver transplantation. Pharmacogenetics. 2004;14 7 471-478.
17. Weilin W, Jing J, Shusen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl. 2006;12 5: 775-780.
18. Yu S, Wu L, Jin J, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation. 2006;81:46- 51.
19. Queteineh L, Verstuyft C. Pharmacogenetics in immunosuppressants: Impact on dose requirement of calcineurin inhibitors in renal and liver paediatric transplant recipients. Curr Opin Organ Transplant. 2010;15:601-607.
20. Mourad M, Wallemacq P, De Meyer M, et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: Impact on pharmacokinetics and clinical outcome. Transplantation. 2008;85(7 Suppl):S19-S24.
21. Hawwa AF, McElnay JC. Impact of ATPbinding cassette, subfamily B, member 1 pharmacogenetics on tacrolimusassociated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. Expert Opin Drug Saf. 2011;10:9-22.
22. Jun KR, Lee W, Jang MS, et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation. 2009;87:1225- 1231.
23. Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of livingdonor liver transplantation. Clin Pharmacol Ther. 2001;69:308-316.
24. Rodriguez S, Gaunt TR, Day IN. HardyWeinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 2009;169(4):505-514.
25. Provenzani A, Notarbartolo M, Labbozzetta M, et al. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann Transplant. 2009;14:23-31.
26. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in livingdonor liver transplant recipients. Pharmacogenet Genomics. 2006;16:119-127.
27. Satoh S, Saito M, Inoue T, et al. CYP3A5-1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2009;65:473-481.
28. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4:914-919.
29. Thevert E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87:721-726.
30. Min SM, Kim SY, Ahn SH, et al. CYP3A5 -1 allele: Impacts on early acute rejection and graft function in tacrolimusbased renal transplant recipients. Transplantation. 2010;90:1394-1400.
31. Provenzani A, Notarbartolo M, Labbozzetta M. et al. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med. 2011;28:1093-1102.
32. de Wildt SN, van Schaik RH, Soldin OP, et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur J Clin Pharmacol. 2011;67:1231-1241.
33. Gorski JC, Hall SD, Becker P, et al. In vivo effects of interleukin10 on human cytochrome P450 activity. Clin Pharmacol Ther. 2000;67:32-41.
34. Masuda S, Goto M, Fukatsu S, et al. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in livingdonor liver transplant patients. Clin Pharmacol Ther. 2006;79:90-102.
35. BarreraPulido L, GuileraGarcia I, DocoboPerez F. et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant Proc. 2008;40:2949-2951.